Risk stratification of pancreatic neuroendocrine neoplasms based on clinical, pathological, and molecular characteristics
JH Choi, WH Paik - Journal of Clinical Medicine, 2022 - mdpi.com
Pancreatic neuroendocrine neoplasms consist of heterogeneous diseases. Depending on
the novel features detected by various modern technologies, their classification and related …
the novel features detected by various modern technologies, their classification and related …
Case report: composite pancreatic intraductal papillary mucinous neoplasm and neuroendocrine tumor: a new mixed neuroendocrine-non-neuroendocrine neoplasm …
J Chen, P Wang, K Lv, W Zhou - Diagnostic Pathology, 2021 - Springer
Background Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) of the
pancreas are extremely rare. Their pathogenesis and molecular landscape are largely …
pancreas are extremely rare. Their pathogenesis and molecular landscape are largely …
Position statement on the diagnosis, treatment, and response evaluation to systemic therapies of advanced neuroendocrine tumors, with a special focus on …
J Capdevila, E Grande, R García-Carbonero… - The …, 2022 - academic.oup.com
Background The aim of this study was to provide a guidance for the management of
neuroendocrine tumors (NETs) in clinical practice. Material and Methods Nominal group and …
neuroendocrine tumors (NETs) in clinical practice. Material and Methods Nominal group and …
Somatostatin receptor activity assessed by 68Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic …
P Mapelli, C Bezzi, F Muffatti, S Ghezzo… - European Journal of …, 2023 - Springer
Purpose To evaluate the role of 68Ga-DOTATOC PET parameters in predicting DAXX/ATRX
loss of expression in patients with Pancreatic neuroendocrine tumors (PanNET) candidate to …
loss of expression in patients with Pancreatic neuroendocrine tumors (PanNET) candidate to …
Detecting Somatic Mutations for Well-Differentiated Pancreatic Neuroendocrine Tumors in Endoscopic Ultrasound-Guided Fine Needle Aspiration with Next …
Abstract Background Pancreatic neuroendocrine tumors (PanNETs) exhibit heterogenous
behavior, whereby some small tumors are aggressive with a propensity for metastasis …
behavior, whereby some small tumors are aggressive with a propensity for metastasis …
[HTML][HTML] Clinical and genomic analyses of neuroendocrine neoplasms of the breast
Y Wei, X Ke, J Yu, Q Jing, H Bu, X Zeng, B Wei - Modern Pathology, 2022 - Elsevier
Breast neuroendocrine neoplasms (NENs) constitute a rare histologic subtype that includes
both neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). In this study …
both neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). In this study …
Enhancer of zeste homolog 2 (EZH2) is a marker of high-grade neuroendocrine neoplasia in gastroenteropancreatic and pulmonary tract and predicts poor prognosis
Simple Summary Neuroendocrine neoplasms most frequently arise in the
gastroenteropancreatic and pulmonary tract and show an increasing incidence and …
gastroenteropancreatic and pulmonary tract and show an increasing incidence and …
[HTML][HTML] Clinicopathological characteristics of nonfunctional pancreatic neuroendocrine neoplasms and the effect of surgical treatment on the prognosis of patients …
A Sadula, G Li, D Xiu, C Ye, S Ren, X Guo… - … Methods in Medicine, 2022 - hindawi.com
Background. The incidence of nonfunctional pancreatic neuroendocrine neoplasms (NF-
pNENs) has been increasing annually. This study is aimed at investigating the …
pNENs) has been increasing annually. This study is aimed at investigating the …
State of the art and future directions in the systemic treatment of neuroendocrine neoplasms
C Jungels, A Deleporte - Current Opinion in Oncology, 2021 - journals.lww.com
State of the art and future directions in the systemic treat... : Current Opinion in Oncology State
of the art and future directions in the systemic treatment of neuroendocrine neoplasms …
of the art and future directions in the systemic treatment of neuroendocrine neoplasms …
EZH2 suppresses insulinoma development by epigenetically reducing KIF4A expression via H3K27me3 modification
S Zhang, J Liu, F Li, M Yang, J Wang - Gene, 2022 - Elsevier
Kinesin family member 4A (KIF4A), located in the human chromosome band Xq13. 1, is
aberrantly overexpressed in various cancers. Our study intended to assess the expression of …
aberrantly overexpressed in various cancers. Our study intended to assess the expression of …